Divergent effects of peroxisome proliferator-activated receptor-γ ligands in human and mouse nonalcoholic steatohepatitis

Hepatology

Volumn 46, Issue 2, 2007, Pages 285-287

  Caldwell, Stephen H ^a   Argo, Curtis K ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BODY FAT; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LIVER FAILURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; FATTY LIVER; HUMANS; LIGANDS; MICE; MICE, OBESE; MITOCHONDRIA, LIVER; PPAR GAMMA; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 34548316135     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21881     Document Type: Editorial

References (25)

1. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
2. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962;14:353-362.
3. Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie 2005;87:57-64.
4. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Martinez MA, Munoz-Yague T, Solis-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. HEPATOLOGY 2007:46:414-423.
5. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2007;46:424-429.
6. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-2422.
7. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002;43:1809-1817.
8. Dedoussis GV, Theodoraki EV, Manios Y, Yiannakouris N, Panagiotakos D, Papoutsakis C, et al. The Pro12Ala polymorphism in PPARgamma2 gene affects lipid parameters in Greek primary school children: A case of gene-to-gender interaction. Am J Med Sci 2007;333:10-15.
9. Shteyer E, Liao Y, Muglia LJ, Hruz PW, Rudnick DA. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. HEPATOLOGY 2004;40:1322-1332.
10. Yang S, Koteish A, Lin H, Huang J, Roskams T, Dawson V, et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. HEPATOLOGY 2004;39:403-411.
11. Laplante M, Festuccia WT, Soucy G, Gelinas Y, Lalonde J, Berger JP, et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006;55:2771-2778.
12. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005;54:1392-1399.
13. Nedergaard J, Petrovic N, Lindgren EM, Jacobsson A, Cannon B. PPAR-gamma in the control of brown adipocyte differentiation. Biochim Biophys Acta 2005;1740:293-304.
14. Caldwell SH, Patrie JT, Brunt EM, Redick JA, Davis CA, Park SH, et al. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. HEPATOLOGY, in press.
15. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-E181.
16. Caldwell SH, Redick JA, Chang CY, Davis CA, Argo CK, Al Osaimi KA. Enlarged hepatocytes in NAFLD examined with osmium fixation: does mictosteatosis underlie cellular ballooning in NASH? Am J Gastroenterol 2006;101:1677-1678.
17. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E1195-E1205.
18. Fujii H, Ikura Y, Iezzoni JC, Kawada N, Ueda M, Caldwell SH. Different expression pattetns of PAT family proteins (perilipin and adipophyllin) in the lipid droplets of NASH. [abstract] HEPATOLOGY 2006;44(Suppl 1):199A.
19. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
20. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Hellar T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-196.
21. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
22. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pto12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
23. Argo CK, Northup PG, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Long-term follow-up of troglitazone therapy in nonalcoholic steatohepatitis patients. Gastroenterology (Suppl) 2006;130:M1948.
24. Ekstedt M, Franzén LE, Marhiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated livet enzymes. HEPATOLOGY 2006;44:865-873.
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356.